Flow Cytometry profiles of TIL co-expressing CD39, CD103, and PD-1 in ovarian cancer

Defining TIL subsets in ovarian cancer which drive prognostic significance. Expression of CD39, CD103, PD-1, and other immune markers was assessed by high-dimensional flow cytometry in matched primary ovarian/ascites patient samples. Healthy donor PBMC were also profiled as a reference control.
Conclusion:
CD39, CD103, and PD-1 are highly co-expressed on ovarian TIL
Notes:
A 20-parameter panel was used to profile cell surface immune checkpoint molecules by spectral flow cytometry on a Cytek Aurora 3 laser (Red/Blue/Violet) instrument(Cytek, Fremont CA). Representative gating strategies and full panel design can be found in the associated manuscript (Title and author list below). Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes co-expressing CD39, CD103, and PD-1 in ovarian cancer Céline M. Laumont, Maartje C.A. Wouters, Julian Smazynski, Nicole S. Gierc, Elizabeth A. Chavez, Lauren C. Chong, Shelby Thornton, Katy Milne, John R. Webb, Christian Steidl, Brad H. Nelson Flow Cytometry Data